Clinical trials: Mental Health Disorder
Alzheimer's Disease
Efficacy and Safety Study of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease
Efficacy and safety study of ABT-288 in adults with mild-to-moderate Alzheimer's disease.
- Trial name
- NCT01018875
- Testing
- ABT-288, donepezil
- Where
- 21 sites in Russia, Ukraine
- Volunteers
- 242 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Depressive Disorder, Major
Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
The purpose of this study is to evaluate the efficacy of vortioxetine, once daily (QD), compared with placebo in adults with major depressive disorder.
- Trial name
- NCT01163266
- Testing
- Vortioxetine
- Where
- 39 sites in United States
- Volunteers
- 462 people
- Sponsor
- Takeda
Sleep Initiation and Maintenance Disorders
15-Day Repeated-Dose Study With SB-649868 And Its Interaction With CYP3A4 Isoenzyme In Healthy Male Subjects.
Subjects will be screened within 28 days, Simvastatin dose and single SB-649868 dose 10 and 7 days prior to repeat dosing respectively, 15 days SB-649868 repeat dosing with safety and cognition function tests.
- Trial name
- NCT00495729
- Testing
- SB-649868, Simvastatin
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Depressive Disorder, Major
A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive Medication
This study is open to adults between 18 and 65 years of age who have depression (major depressive disorder). People with a current depressive episode lasting between 2 months and one and a half years can join the study.
- Trial name
- NCT04937829
- Testing
- 5 mg BI 1569912, 20 mg BI 1569912
- Where
- 10 sites in United States
- Volunteers
- 59 people
- Sponsor
- Boehringer Ingelheim
Schizophrenia
An Efficacy and Safety Study of 3 Fixed Doses of JNJ-37822681 in Participants With Schizophrenia
The purpose of this study is to evaluate the efficacy and safety of 3 fixed doses of JNJ-37822681 compared with placebo (an inactive substance that is compared with a drug to test if the drug has a real effect in a clinical…
- Trial name
- NCT00728195
- Testing
- JNJ-37822681, Olanzapine
- Where
- 45 sites in Bulgaria, Estonia and 8 more
- Volunteers
- 498 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Subjective Sleep Quality, Objective Sleep Quality
Effect of B. Longum 1714™ on Sleep Quality
The aim of this study is to evaluate the effect of supplementation with the B. longum 1714™ strain on subjective and objective sleep quality in healthy participants.
- Trial name
- NCT04167475
- Testing
- Probiotic capsule
- Where
- Ireland
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- PrecisionBiotics Group Ltd.
Opioid Induced Constipation
Evaluation of the Efficacy and Safety of ADL5945 for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain
Morphine and related opioid analgesics are known to slow gastrointestinal (GI) motility and reduce intestinal secretion through their binding to μ opioid receptors (MORs) within the GI tract.
- Trial name
- NCT01207427
- Testing
- ADL5945 0.1 mg, ADL5945 0.25 mg
- Volunteers
- 131 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Stress Disorder, Stress
Sensate II Utilization and Perceived Stress in Adults
Sensate® is A commercially marketed (FCC #: 2AS9ESEN231) stress management wellness device (BioSelf Technology; London, UK). This non-invasive wellness device is one component of a cross-modal (acoustic and aural) sensory…
- Trial name
- NCT05519995
- Where
- United Kingdom
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- BioSelf Technology
Major Depressive Disorder
Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder
This randomized, double-blind, placebo-controlled, multicenter study will evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD).
- Trial name
- NCT06058039
- Testing
- NMRA-335140
- Where
- 71 sites in United States, Bulgaria and 6 more
- Volunteers
- 422 people
- Sponsor
- Neumora Therapeutics, Inc.
Schizophrenia, Mania
Aripiprazole Pharmacokinetics (PK) and Tolerability Study in Children and Adolescents
The purpose of this trial is to assess the safety, tolerability and pharmacokinetics of aripiprazole tablets following oral administration to children and adolescents.
- Trial name
- NCT00102479
- Testing
- Aripiprazole
- Volunteers
- 21 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Parkinson's Disease, Restless Leg Syndrome
A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Und Fasted Conditions
The objective of this study was to assess the single dose bioequivalence of Roxane's Ropinirole Tablets, 0.25 mg to ReQuip Tablets, 0.25 mg (GlaxoSmithKline) under fasting conditions using a single-dose, randomized, 2-treatment…
- Trial name
- NCT00673088
- Testing
- Ropinirole Hydrochloride
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Alzheimer's Disease
Safety and Tolerability of Rivastigmine With Add-on Memantine in Patients With Probable Alzheimer's Disease
This is a prospective, 26-week, open-label, single-arm multi-center pilot study. Eligible patients will receive open-label treatment with rivastigmine capsules plus memantine tablets as add on therapy.
- Trial name
- NCT00305903
- Testing
- Rivastigmine, memantine
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Novartis
Major Depressive Disorder, Healthy Participants
A Study of the Neurobiology of Depression
Previous research studies have shown that depression is associated with changes in structure and activity in different parts of the brain and that antidepressant medication can affect brain activity in different parts of the…
- Trial name
- NCT01051466
- Testing
- Duloxetine
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease, Healthy Volunteer
Single-Ascending-Dose Study of BIIB076 in Healthy Volunteers and Participants With Alzheimer's Disease
The primary objective of the study is to evaluate the safety and tolerability of single-ascending intravenous (IV) infusions of BIIB076 in healthy volunteers and participants with Alzheimer's disease (AD).
- Trial name
- NCT03056729
- Testing
- BIIB076
- Where
- 8 sites in United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Biogen
Alzheimer's Disease
A Study to Evaluate the Use of an Indwelling Catheter to Obtain Cerebrospinal Fluid (CSF) by Low-rate Continuous Sampling (MK-0000-211)
This is a study to evaluate the feasibility and tolerability of low-rate continuous Cerebrospinal Fluid (CSF) sampling and to estimate the number of participants who exhibit severe baseline instability of CSF amyloid beta isoform…
- Trial name
- NCT01325662
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Bipolar Disorder, Bipolar Depression
Seroquel in Bipolar Depression Versus Lithium
This study is being carried out to see if quetiapine fumarate (Seroquel) is effective in treating bipolar depression during an 8-week acute phase compared with placebo and lithium, followed by continuation treatment for 26 up to…
- Conditions
- Bipolar Disorder, Bipolar Depression, Depression
- Trial name
- NCT00206141
- Testing
- Quetiapine Fumarate (Seroquel™) drug, mood stabilizer (mood)
- Where
- 76 sites in Canada, Croatia and 14 more
- Volunteers
- 672 people
- Sponsor
- AstraZeneca
Sleep Apnea, Hypersomnia
Patient Outcomes in Unattended and In- Lab Polysomnography
This randomized controlled study will directly evaluate whether unattended polysomnography (level 2 sleep study) in individuals referred for sleep apnea or hypersomnia, including those with comorbidities of insomnia and…
- Trial name
- NCT05230394
- Testing
- Attended Polysomnography in the Lab, Unattended Polysomnography in the Home
- Where
- Canada
- Volunteers
- 194 people, healthy volunteers welcome
- Sponsor
- Cerebra Medical
Sleep Disorders
Efficacy and Safety of Circadin® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities
The purpose of this study is to establish the efficacy and safety of Circadin in children with neurodevelopmental disorders and to determine the dose, this randomized, placebo-controlled study is planned to evaluate the efficacy…
- Trial name
- NCT01906866
- Testing
- Circadin 2/5/10 mg
- Where
- 28 sites in United States, Finland and 3 more
- Volunteers
- 125 people
- Sponsor
- Neurim Pharmaceuticals Ltd.
Schizophrenia
Effect of Quetiapine on Negative Symptoms and Cognition
The purpose of the study is to investigate the outcome on negative symptoms of schizophrenic patients during therapy with quetiapine or risperidone.
- Trial name
- NCT00305422
- Testing
- Quetiapine fumarate, Risperidone
- Where
- Germany
- Volunteers
- 45 people
- Sponsor
- AstraZeneca
Alzheimer's Disease
Rivastigmine Monotherapy and Combination Therapy With Memantine in Patients With Moderately Severe Alzheimer's Disease Who Failed to Benefit From Previous Cholinesterase Inhibitor Treatment
This is a prospective, multicenter, open-label study. Following screening and baseline assessments, eligible patients will be switched to rivastigmine and will enter the 16 week run-in rivastigmine treatment phase.
- Trial name
- NCT00234637
- Testing
- Rivastigmine, memantine
- Where
- France
- Volunteers
- 204 people
- Sponsor
- Novartis
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.